Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.

BACKGROUND Early-phase and preclinical studies suggest that moxifloxacin-containing regimens could allow for effective 4-month treatment of uncomplicated, smear-positive pulmonary tuberculosis. METHODS We conducted a randomized, double-blind, placebo-controlled, phase 3 trial to test the noninferiority of two moxifloxacin-containing regimens as compared with a control regimen. One group of patients received isoniazid, rifampin, pyrazinamide, and ethambutol for 8 weeks, followed by 18 weeks of isoniazid and rifampin (control group). In the second group, we replaced ethambutol with moxifloxacin for 17 weeks, followed by 9 weeks of placebo (isoniazid group), and in the third group, we replaced isoniazid with moxifloxacin for 17 weeks, followed by 9 weeks of placebo (ethambutol group). The primary end point was treatment failure or relapse within 18 months after randomization. RESULTS Of the 1931 patients who underwent randomization, in the per-protocol analysis, a favorable outcome was reported in fewer patients in the isoniazid group (85%) and the ethambutol group (80%) than in the control group (92%), for a difference favoring the control group of 6.1 percentage points (97.5% confidence interval [CI], 1.7 to 10.5) versus the isoniazid group and 11.4 percentage points (97.5% CI, 6.7 to 16.1) versus the ethambutol group. Results were consistent in the modified intention-to-treat analysis and all sensitivity analyses. The hazard ratios for the time to culture negativity in both solid and liquid mediums for the isoniazid and ethambutol groups, as compared with the control group, ranged from 1.17 to 1.25, indicating a shorter duration, with the lower bounds of the 95% confidence intervals exceeding 1.00 in all cases. There was no significant difference in the incidence of grade 3 or 4 adverse events, with events reported in 127 patients (19%) in the isoniazid group, 111 (17%) in the ethambutol group, and 123 (19%) in the control group. CONCLUSIONS The two moxifloxacin-containing regimens produced a more rapid initial decline in bacterial load, as compared with the control group. However, noninferiority for these regimens was not shown, which indicates that shortening treatment to 4 months was not effective in this setting. (Funded by the Global Alliance for TB Drug Development and others; REMoxTB ClinicalTrials.gov number, NCT00864383.).

[1]  Julian Parkhill,et al.  Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study , 2013, The Lancet. Respiratory medicine.

[2]  K. Fielding,et al.  An Evaluation of Culture Results during Treatment for Tuberculosis as Surrogate Endpoints for Treatment Failure and Relapse , 2013, PloS one.

[3]  A. Diacon,et al.  14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial , 2012, The Lancet.

[4]  Richard G. White,et al.  WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update , 2011, European Respiratory Journal.

[5]  A. Nunn,et al.  Results at 30 months of a randomised trial of two 8-month regimens for the treatment of tuberculosis. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[6]  A. Ginsberg.  Tuberculosis drug development: progress, challenges, and the road ahead. , 2010, Tuberculosis.

[7]  D. Mitchison,et al.  Timing of relapse in short-course chemotherapy trials for tuberculosis. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[8]  J. Fitzgerald,et al.  Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis , 2009, PloS one.

[9]  Charles M Heilig,et al.  Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. , 2009, American journal of respiratory and critical care medicine.

[10]  William R Bishai,et al.  Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial , 2009, The Lancet.

[11]  D. Mitchison,et al.  A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[12]  John L. Johnson,et al.  Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. , 2006, American journal of respiratory and critical care medicine.

[13]  Alexander Kopp,et al.  Outpatient gatifloxacin therapy and dysglycemia in older adults. , 2006, The New England journal of medicine.

[14]  R. Chaisson,et al.  Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. , 2004, American journal of respiratory and critical care medicine.

[15]  H. Lode,et al.  Early Bactericidal Activity of Moxifloxacin in Treatment of Pulmonary Tuberculosis: a Prospective, Randomized Study , 2004, Antimicrobial Agents and Chemotherapy.

[16]  R. Chaisson,et al.  Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. , 2004, American journal of respiratory and critical care medicine.

[17]  S. Gillespie,et al.  The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. , 2003, American Journal of Respiratory and Critical Care Medicine.

[18]  G. Zhanel,et al.  Fluoroquinolone-associated tendinopathy: a critical review of the literature. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  H. Lode,et al.  Comparative Pharmacokinetics of Ciprofloxacin, Gatifloxacin, Grepafloxacin, Levofloxacin, Trovafloxacin, and Moxifloxacin after Single Oral Administration in Healthy Volunteers , 2000, Antimicrobial Agents and Chemotherapy.

[20]  J. T. Sullivan,et al.  Pharmacokinetics of a Once-Daily Oral Dose of Moxifloxacin (Bay 12-8039), a New Enantiomerically Pure 8-Methoxy Quinolone , 1999, Antimicrobial Agents and Chemotherapy.

[21]  H. Eichler,et al.  Penetration of Moxifloxacin into Peripheral Compartments in Humans , 1999, Antimicrobial Agents and Chemotherapy.

[22]  O. Billington,et al.  Activity of moxifloxacin against mycobacteria. , 1999, The Journal of antimicrobial chemotherapy.

[23]  A. Tice,et al.  Short-course therapy of acute cystitis: a brief review of therapeutic strategies. , 1999, The Journal of antimicrobial chemotherapy.

[24]  R. Chaisson,et al.  Moxifloxacin (BAY12-8039), a New 8-Methoxyquinolone, Is Active in a Mouse Model of Tuberculosis , 1999, Antimicrobial Agents and Chemotherapy.

[25]  A. Nunn,et al.  [Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy]. , 1978, Bulletin of the International Union against Tuberculosis.

[26]  F. Blasi,et al.  Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones. , 2014, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[27]  S. Mwaigwisya,et al.  Whole-genome sequencing to establish relapse or reinfection with Mycobacterium tuberculosis : a retrospective observational study , 2013 .

[28]  Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001. , 2001, MMWR. Morbidity and mortality weekly report.

[29]  Tuberculosis Service/British Medic Singapore.  Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months. , 1981, Tubercle.